Lazard Asset Management
TLOG

Lazard Asset Management’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Lazard Asset Management’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-75,000
Closed -$13K – 1147
2016
Q1 		$13K Buy
+75,000
New +$20.8K ﹤0.01% 940
2015
Q3 		– Sell
-90,436
Closed -$211K – 1209
2015
Q2 		$211K Buy
+90,436
New +$279K ﹤0.01% 832

Other funds holding TLOG

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $15.9B AUM 53.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Lazard Asset Management's TLOG Position: Q2 2016 in Review

Lazard Asset Management sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2016, closing a stake of 75,000 shares — an estimated $13K sold.

Lazard Asset Management first reported a position in TLOG in Q2 2015 and held it in 2 quarters. The position peaked at $211K in Q2 2015. 19 funds tracked by Wall St. Rank hold TLOG as of Q2 2016.

  • Lazard Asset Management reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2016 after selling out during the quarter.
  • Lazard Asset Management sold 75,000 TetraLogic Pharmaceuticals Corporation shares in Q2 2016, an estimated $13K.
  • Lazard Asset Management first reported a position in TetraLogic Pharmaceuticals Corporation in Q2 2015 and held it in 2 quarters.
  • Lazard Asset Management's TetraLogic Pharmaceuticals Corporation position peaked at $211K in Q2 2015.
  • 19 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2016.

Based on Lazard Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.